B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple Sclerosis
Clinical trial NCT05296161 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05296161
- Sponsor
- Amsterdam UMC, location VUmc
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2022-04-20
- Primary completion
- 2027-02-01
- Enrollment
- 296
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.